Reprogrammed Stem Cells Are Rife with Mutations
The findings cast doubt on a promising alternative to the use of embryonic stem cells in medicine.
Adult cells that have been reprogrammed into stem cells harbor a number of genetic mutations, some of which appear in genes that have been linked to cancer. While scientists don’t yet know how this might affect the use of the cells in medicine, they say the findings show that the cells need to be studied much more extensively.
“As we think about using [these] cells for therapy, we will want to consider what kinds of screening tests we want to do,” says Lawrence Goldstein, a professor of molecular biology at the University of California, San Diego. One of the major concerns about stem-cell-based therapies has been whether they carry a risk of cancer; both stem cells and cancer cells are distinguished by their ability to continually divide.
In two studies published today in Nature, researchers analyzed the genome of induced pluripotent stem (iPS) cells, adult cells that have been genetically or chemically reverted to the stem cell state. These cells have attracted intense interest from both scientists and the public as a potential alternative to embryonic stem cells. Like their embryo-derived cousins, iPS cells can develop into any type of tissue, making them a good candidate for cell-replacement therapies. They are also genetically matched to the patient, meaning they don’t carry the risk of immune rejection associated with existing cell transplants.
In one study, Goldstein, Kun Zhang, and collaborators at the University of California, San Diego, sequenced the gene-coding portion of the genome in 22 iPS cell lines that had been reprogrammed using several different methods. “Every cell line we looked at, we found single [genetic-letter] mutations in the protein-coding region, an average of six mutations per cell line,” says Zhang.
Different cell lines had mutations in different genes, but a disproportionate number of the mutations appeared in genes involved in cell growth or in genes that have been previously linked to cancer.
Some of the mutations probably arise from the evolutionary pressure of growing in a dish. If a random mutation that occurs during cell division helps daughter cells grow faster than others, that mutation will take root in the population. However, Zhang’s team found that the mutation rate in iPS cells is 10 times the typical rate for cultured cells.
It’s not yet clear why iPS cells have such a high mutation rate. Researchers found that roughly half the mutations occurred before reprogramming and could be found in a few cells in the initial population from which the iPS cells were derived. The others might have occurred during the process of reprogramming or as the newly created iPS cells grew. The team is now planning similar tests of embryonic stem cells.
In the second study in Nature, researchers from Canada and Finland used microarrays—chips dotted with pieces of target DNA—to analyze another type of genetic mutation in iPS cells: small deletions or duplications of DNA known as structural variations. They found that iPS cells had more of these variations than either skin cells or embryonic stem cells did early in the reprogramming process but that cells bearing abnormalities quickly died off as the population continued to grow.
Researchers say that more research is needed to understand what the findings mean for future use of these cells in therapies. “The big question is which of these changes really matter,” says Jeanne Loring, director of the Center for Regenerative Medicine at Scripps Research Institute. “We need to figure out which are relevant and which are just noise.” Loring has published results similar to the second study this year.
“For some type of genetic changes—mutations in cancer-linked genes, for example—we clearly would not want to use cells in patients,” says Martin Pera, director of the Broad Center for Regenerative Medicine at the University of Southern California, who wrote a commentary accompanying the publication in Nature. “But for the vast range of changes, we don’t really understand functional significance.” As is the case in many genomics studies, “the ability to collect in-depth genetic information has outstripped our ability to interpret it,” he says. “That’s the real challenge going forward.”
Part of the problem is that scientists know little about the mechanisms underlying reprogramming. “We can’t yet identify what particular aspect of the reprogramming process or cell culture is responsible for engendering these changes,” says Pera. “If we want to fix this, we need to understand what aspect of the process is critical.”
Learn today what the rest of the world won’t know until tomorrow, at Business of Blockchain 2019.Register now